News | Robotic Systems | December 06, 2017

Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System

New funding aims to increase resources available for marketing and development of the next generation of robotics dedicated to the treatment of strokes

Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System

December 6, 2017 — French company Robocath, which designs and develops robotic solutions for the treatment of vascular diseases, announced an increase in capital of €1.7 million ($2 million). This is partly thanks to a €1.25 million ($1.5 million) contribution from Crédit Agricole Innovations et Territoires (CAIT), a fund dedicated to technological innovation in France, managed by Supernova Invest. Cardio Participation, a holding company bringing together several business angels, also invested €450,000 ($530,000). This latest financial contribution supplements the €4.7 million ($5.6 million) raised by Robocath in a previous round of fundraising in May.

Robocath’s R-One technology optimizes and increases the safety of robotic-assisted coronary angioplasty. The technology allows the surgeon to operate with extreme precision and in optimal conditions. Intuitive to use, R-One allows the surgeon to operate from a seated position and to use a portable protective screen to guard against X-rays. This first robotic platform will be marketed in Europe and the Middle East in 2018.

Thanks to this funding, Robocath will also begin researching and developing the next generation of robotic solutions. The new platform will be used to treat neurovascular diseases such as strokes, the second leading cause of death in the world after hearts attacks. The new solution will also aim to improve care for these conditions.

For more information: www.robocath.com

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init